Compare

    Two terms, side by side

    Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

    Curated comparison tables

    In-depth, attribute-by-attribute tables for the most common MedTech term pairs. Each row is sourced from the linked term pages.

    Post-Market

    Medical Device Reporting (FDA)(MDR)

    In one line
    FDA mechanism for receiving reports of device-related deaths, serious injuries, and malfunctions.
    Definition
    Medical Device Reporting under 21 CFR Part 803 requires manufacturers, importers, and device user facilities to report device-related deaths, serious injuries, and certain malfunctions to FDA within defined timeframes. Manufacturers must file a 30-day report for deaths, serious injuries and malfunctions that would likely cause or contribute to death or serious injury if they recurred, and a 5-day report when remedial action is needed to prevent unreasonable risk or FDA requests it. User facilities report deaths to FDA and the manufacturer and serious injuries to the manufacturer. FDA publishes reports in the MAUDE database, and some malfunctions qualify for quarterly summary reporting under the VMSR program.
    Why it matters
    Not to be confused with the EU Medical Device Regulation. FDA MDR data is publicly searchable through the MAUDE database.
    Common pitfalls
    • •Failing to distinguish between reportable malfunctions and those that do not meet the criteria for Medical Device Reporting can lead to non-compliance.
    • •Delaying the submission of a report due to incomplete information, rather than submitting a timely initial report with a follow-up, is a common pitfall.
    • •Not adequately training personnel on the criteria and procedures for identifying and reporting adverse events can result in missed reports.
    • •Confusing the reporting requirements for manufacturers with those for user facilities or importers can lead to incorrect submissions.
    • •Underreporting subtle device malfunctions that, if recurrent, could escalate to serious harm is a significant oversight.
    Open full page
    Select term B to compare.

    Why compare MedTech terms side by side?

    MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

    Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

    Common comparison patterns

    How to use this tool

    Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

    MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.